MedTrace Logo

Calciphylaxis : Population, Risk Factors, Diagnostic Practice, Therapeutic and Outcome

NCT02854046 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2021-09-21

No results posted yet for this study

Summary

Calciphylaxis, also called Calcific Uremic Arteriolopathy (CUA) is a lethal affection mostly affecting patient in end stage renal disease. The survival rate is described around 20 to 46% at one year.

Clinical presentation is very painful skin lesions with ulceration mostly located on the trunk or thigh.

Current knowledge about physiopathology, diagnostic practice and therapeutic is very limited.

Actually there is no European study about calciphylaxis and risk factors, diagnostic practice and outcome factors.

Conditions

  • Calciphylaxis

Interventions

OTHER

Calcific Uremic Arteriolopathy

Sponsors & Collaborators

  • Nantes University Hospital

    lead OTHER

Principal Investigators

  • Maryvonne HOURMANT, PHD · Nantes University Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-07-01
Primary Completion
2016-10-31
Completion
2016-10-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02854046 on ClinicalTrials.gov